Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial

COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas

(2021) Xianwen Ren et al.   CELL

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

(2021) David S. Khoury et al.   NATURE MEDICINE

Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study

(2021) Jingxin Li et al.   NATURE MEDICINE

A novel coronavirus outbreak of global health concern

(2020) Chen Wang et al.   LANCET

A Novel Coronavirus from Patients with Pneumonia in China, 2019

(2020) Na Zhu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

(2020) Feng-Cai Zhu et al.   LANCET

Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19

(2020) Mingfeng Liao et al.   NATURE MEDICINE

Rapid COVID-19 vaccine development

(2020) Barney S. Graham   SCIENCE

A Thermostable mRNA Vaccine against COVID-19

(2020) Na-Na Zhang et al.   CELL

A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2

(2020) Wanbo Tai et al.   CELL RESEARCH

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

(2020) Pedro M Folegatti et al.   LANCET

Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults

(2020) Mark J. Mulligan et al.   NATURE

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

(2020) Lisa A. Jackson et al.   NEW ENGLAND JOURNAL OF MEDICINE

The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients

(2020) Lakshmanane Premkumar et al.   Science Immunology

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

(2020) Takuya Sekine et al.   CELL

COVID-19 Makes B Cells Forget, but T Cells Remember

(2020) Pablo F. Cañete et al.   CELL

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

(2020) Edward E. Walsh et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement

(2020) Jinkai Zang et al.   Cell Discovery

Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19

(2020) Lauren B. Rodda et al.   CELL

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

(2020) Lindsey R. Baden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed rabies vaccine in a first-in-human trial

(2019) Fatma Doener et al.   VACCINE

mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases

(2019) Giulietta Maruggi et al.   MOLECULAR THERAPY

Tailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response

(2019) Sergio Linares-Fernández et al.   TRENDS IN MOLECULAR MEDICINE

Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection

(2016) Oi-Wing Ng et al.   VACCINE